Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment1Abbreviations: AIA, antiinsulin antibody; CAPD, continuous ambulatory dialysis; CSII, continuous subcutaneous insulin infusion; DCCT, diabetes control complications trial; FIR, far infrared radiation; GLP1, glucagon-like peptide 1; GH, growth hormone; HbA1c, glycated hemoglobin; IDDM, insulin-dependent diabetes mellitus; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; ISF, interstitial fluid; ISGIID, International Study Group on Implantable Insulin Delivery Devices; i.v., intravenous; MDI, multiple daily injections; NIDDM, non-insulin-dependent diabetes mellitus; PAI1, plasminogen activator inhibitor 1; rh IGF1, recombinant human insulin-like growth factor 1; SHBG, sex hormone binding globulin; SC, subcutaneous; SMBG, self monitoring of blood glucose; TG, triglycerides.1-Reference-Cited by-同舟云学术

Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment1Abbreviations: AIA, antiinsulin antibody; CAPD, continuous ambulatory dialysis; CSII, continuous subcutaneous insulin infusion; DCCT, diabetes control complications trial; FIR, far infrared radiation; GLP1, glucagon-like peptide 1; GH, growth hormone; HbA1c, glycated hemoglobin; IDDM, insulin-dependent diabetes mellitus; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; ISF, interstitial fluid; ISGIID, International Study Group on Implantable Insulin Delivery Devices; i.v., intravenous; MDI, multiple daily injections; NIDDM, non-insulin-dependent diabetes mellitus; PAI1, plasminogen activator inhibitor 1; rh IGF1, recombinant human insulin-like growth factor 1; SHBG, sex hormone binding globulin; SC, subcutaneous; SMBG, self monitoring of blood glucose; TG, triglycerides.1

Published:1999-02 Issue:2-3 Volume:35 Page:179-198
ISSN:0169-409X
Container-title:Advanced Drug Delivery Reviews
language:en
Short-container-title:Advanced Drug Delivery Reviews

Author:

Jeandidier Nathalie,Boivin Sophie

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference113 articles.

1. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (1993) 977–986.

2. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM;Kerstin;Diabetes,1996

3. C. Abraira, J. Colwell, F. Nuttall, C. Sawin, N. Johnson-Nagel, J. Comstock, N. Emanuele, S. Levin, W. Henderson, H. Lee, VA CDSM Group, Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CDSM). Results of a feasibility trial, Diabetes Care 18 (1995) 1113–1123.

4. American Diabetes Association, Implications of the Diabetes Control and Complications Trial, Diabetes Care 21 (1998) S88–90.

5. Excess costs of medical care for patients with diabetes in a managed care population;Selby;Diabetes Care,1997

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in glucose-oxidase-based nanocomposites for diabetes diagnosis and treatment;Journal of Materials Chemistry B;2023

2. Glucose-responsive nanogate of poly(methacrylic acid) brush-glucosamine network capping on the holes of chips for controlled insulin release;Journal of the Taiwan Institute of Chemical Engineers;2022-12

3. Engineered Nanomaterials as Drug Delivery Systems and Biomedicines;Nanotechnology in the Life Sciences;2022

4. Microgel encapsulated nanoparticles for glucose-responsive insulin delivery;Biomaterials;2021-01

5. pH-sensitive MOF integrated with glucose oxidase for glucose-responsive insulin delivery;Journal of Controlled Release;2020-04